Christopher Owens

Virology
Cambridge University Press
Indonesia

Business Expert Microbiology
Biography

 Molecular Biologist/Virologist with 13 years experience in drug development and managing scientific teams. CAREER ACCOMPLISHMENTS • Co-discovered TRIM5-alpha, a cellular post-entry inhibitor of HIV-1 infection, resulting in a new field of HIV research. • Built a Hepatitis C antiviral screening program that ultimately led to the contribution of a new lead, CRx-808, to the CombinatoRx pipeline in less than 2 years, with eventual completion of a phase I clinical trial. • Provided preclinical and clinical support for EDP-239, an Enanta Pharmaceuticals HCV NS5A inhibitor licensed by Novartis for $34M up front and up to $404M more in milestone payments. • Clinical virology support for EDP-494 IND and phase 1a/1b, including investigator brochure and research protocol.

Research Intrest

 Research on Virology & Infectious Diseases